Barclays PLC Increases Icon Plc (ICLR) Price Target to $120.00

Icon Plc (NASDAQ:ICLR) had its price objective boosted by Barclays PLC from $108.00 to $120.00 in a research note released on Friday, October 27th, MarketBeat.com reports. The brokerage currently has an equal weight rating on the medical research company’s stock.

Several other research firms have also recently issued reports on ICLR. Zacks Investment Research cut Icon Plc from a buy rating to a hold rating in a research note on Friday, September 22nd. Jefferies Group LLC reissued a buy rating and issued a $122.00 price target on shares of Icon Plc in a research note on Tuesday, September 12th. ValuEngine cut Icon Plc from a buy rating to a hold rating in a research note on Monday, October 2nd. SunTrust Banks, Inc. raised Icon Plc from a hold rating to a buy rating and increased their price target for the stock from $93.00 to $126.00 in a research note on Monday, July 31st. Finally, Mizuho raised their target price on Icon Plc from $104.00 to $108.00 and gave the company a neutral rating in a research note on Thursday, July 27th. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $121.00.

Icon Plc (NASDAQ:ICLR) traded down $0.57 during mid-day trading on Friday, hitting $113.24. The company had a trading volume of 360,600 shares, compared to its average volume of 368,772. The firm has a market cap of $6,120.00, a price-to-earnings ratio of 21.84, a P/E/G ratio of 1.76 and a beta of 0.62. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90. Icon Plc has a twelve month low of $73.76 and a twelve month high of $124.48.

Icon Plc (NASDAQ:ICLR) last issued its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.03. The firm had revenue of $440.30 million during the quarter, compared to the consensus estimate of $438.09 million. Icon Plc had a return on equity of 28.42% and a net margin of 16.37%. The firm’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.19 EPS. equities research analysts forecast that Icon Plc will post 5.36 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://weekherald.com/2017/11/15/barclays-plc-boosts-icon-plc-iclr-price-target-to-120-00.html.

A number of hedge funds have recently modified their holdings of ICLR. Koch Industries Inc. increased its position in Icon Plc by 17,508.8% in the 2nd quarter. Koch Industries Inc. now owns 666,140 shares of the medical research company’s stock worth $659,000 after purchasing an additional 662,357 shares during the last quarter. FMR LLC increased its holdings in shares of Icon Plc by 38.4% during the 2nd quarter. FMR LLC now owns 2,291,005 shares of the medical research company’s stock valued at $224,037,000 after acquiring an additional 635,950 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Icon Plc by 48.4% during the 2nd quarter. Janus Henderson Group PLC now owns 1,068,159 shares of the medical research company’s stock valued at $104,488,000 after acquiring an additional 348,292 shares during the last quarter. Mckinley Capital Management LLC Delaware increased its holdings in shares of Icon Plc by 2,674.8% during the 2nd quarter. Mckinley Capital Management LLC Delaware now owns 338,520 shares of the medical research company’s stock valued at $33,104,000 after acquiring an additional 326,320 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of Icon Plc by 71.5% during the 3rd quarter. Principal Financial Group Inc. now owns 768,471 shares of the medical research company’s stock valued at $87,513,000 after acquiring an additional 320,356 shares during the last quarter. 91.59% of the stock is currently owned by institutional investors.

About Icon Plc

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Analyst Recommendations for Icon Plc (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply